Is overall survival a useful endpoint for evaluating therapies for intermediate-risk patients?

In a recent commentary, we looked at the utility of surrogate endpoints in evaluating therapies. … READ MORE …

So … what IS going to be “hot” at ASCO this year?

It appears that when it comes to the new data to be presented at ASCO this year, this will be the first time for several years that we don’t see some really groundbreaking new data from a large Phase III trial of some new form of therapy at one of the major meetings. But there is a lot of detail and a lot of information about new trials in development. … READ MORE …

Can the “bone scan index” act as a surrogate marker for survival?

One of the problems with clinical trials for late-stage prostate cancer today is that we commonly need to follow all patients until death before we can collect sufficiently accurate data to be certain that a particular product is or is not effective in extending patient survival. … READ MORE …

Small problem in evaluation of NX-1207 in early stage, low-risk prostate cancer

Now here’s an  embarrassing admission for a drug development company to have to make … READ MORE …

Evaluation of the real utility of new biomarkers for prostate cancer risk

There is a fascinating comment by Kattan scheduled for publication in a forthcoming issue of the new journal Urology Practice. It makes a truly critical point about whether any of the new biomarkers are actually adding significantly to what we know about how to assess risk for prostate cancer. … READ MORE …

The FDA’s “take” on pre-chemo approval of abiraterone in mCRPC

A new article in Clinical Cancer Research offers us insights into the US Food and Drug Administration’s thinking about the approval of abiraterone acetate for the treatment of chemotherapy-naive patients with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Prostate Cancer Roundtable updates national policy agenda

The Prostate Cancer Roundtable has just announced an update to its national policy agenda — to include a focus on the importance of patient-reported outcomes data affecting quality of life in trials designed with survival as the primary endpoint. … READ MORE …